Carlton Hofferkamp & Jenks Wealth Management Raised T J X Cos (TJX) Position By $337,479; Harvard Bioscience (HBIO) Shorts Lowered By 1.03%

December 26, 2017 - By Danny Collins

Harvard Bioscience Incorporated (NASDAQ:HBIO) had a decrease of 1.03% in short interest. HBIO’s SI was 540,000 shares in December as released by FINRA. Its down 1.03% from 545,600 shares previously. With 33,800 avg volume, 16 days are for Harvard Bioscience Incorporated (NASDAQ:HBIO)’s short sellers to cover HBIO’s short positions. The SI to Harvard Bioscience Incorporated’s float is 1.83%. The stock decreased 0.78% or $0.02 during the last trading session, reaching $3.2. About 27,047 shares traded. Harvard Bioscience, Inc. (NASDAQ:HBIO) has declined 25.93% since December 26, 2016 and is downtrending. It has underperformed by 42.63% the S&P500.

Carlton Hofferkamp & Jenks Wealth Management Llc increased T J X Cos Inc (TJX) stake by 16.18% reported in 2017Q3 SEC filing. Carlton Hofferkamp & Jenks Wealth Management Llc acquired 4,623 shares as T J X Cos Inc (TJX)’s stock declined 3.78%. The Carlton Hofferkamp & Jenks Wealth Management Llc holds 33,198 shares with $2.45 million value, up from 28,575 last quarter. T J X Cos Inc now has $48.21 billion valuation. The stock decreased 0.07% or $0.05 during the last trading session, reaching $76.25. About 3.00 million shares traded. The TJX Companies, Inc. (NYSE:TJX) has declined 2.02% since December 26, 2016 and is downtrending. It has underperformed by 18.72% the S&P500.

Investors sentiment decreased to 0.91 in 2017 Q3. Its down 0.18, from 1.09 in 2017Q2. It dived, as 8 investors sold Harvard Bioscience, Inc. shares while 15 reduced holdings. 7 funds opened positions while 14 raised stakes. 21.49 million shares or 1.39% more from 21.19 million shares in 2017Q2 were reported. Utd Ser Automobile Association reported 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Morgan Stanley invested in 25,446 shares. Moreover, First Manhattan has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 131,000 shares. Axa invested 0% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Essex Invest Lc has 0.28% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO). Vanguard owns 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 1.57 million shares. Geode Capital Limited Liability Corporation accumulated 0% or 146,791 shares. Manufacturers Life Insur Communications The stated it has 2,568 shares. 605,045 are held by Renaissance Technologies Ltd Limited Liability Company. Sei Invs Com has invested 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Price T Rowe Assocs Inc Md accumulated 28,200 shares or 0% of the stock. Nationwide Fund Advisors has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO). Clarivest Asset Mngmt Ltd Liability invested in 160,500 shares. Woodmont Counsel Limited Liability holds 177,491 shares. Panagora Asset Mngmt has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 10,265 shares.

Among 2 analysts covering Harvard Bioscience Inc (NASDAQ:HBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harvard Bioscience Inc had 2 analyst reports since July 28, 2015 according to SRatingsIntel. As per Thursday, November 17, the company rating was initiated by Singular Research. Benchmark initiated the stock with “Buy” rating in Tuesday, July 28 report.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $111.62 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

Since September 1, 2017, it had 0 insider purchases, and 1 sale for $1.45 million activity. The insider Herrman Ernie sold $1.45 million.